Oliver Rolf Baumann net worth and biography

Oliver Baumann Biography and Net Worth

Director of Veraxa Biotech

Oliver R. Baumann is a dynamic financial executive with more than 15 years of leadership experience in the investment and life sciences sectors. As the CEO and Partner of Xlife Sciences AG since 2019, he has successfully led corporate strategy, M&A transactions, strategic partnerships, and out-licensing initiatives, driving value creation and global market access. His expertise in portfolio management, cross-border deal structuring, and governance has been instrumental in building a robust network of Subsidiaries and international partnerships. Previously, Oliver held senior roles at Sloan Asset Management AG, where he progressed from Senior Investment Analyst to CEO and Partner. His work encompassed business development, risk management, compliance, and trading operations across diverse asset classes. Earlier in his career, Oliver gained foundational financial experience at Credit Suisse AG, managing client portfolios, developing investment strategies, and producing market research. Oliver’s board memberships span several biotech, life sciences, and investment companies, underscoring his broad industry impact. He holds a Swiss State-Certified Banking Economist diploma and has completed advanced training in technical analysis and languages. With strong analytical skills, strategic foresight, and a collaborative leadership style, Oliver Baumann is dedicated to unlocking value and driving innovation in the life sciences and investment sectors.

What is Oliver Rolf Baumann's net worth?: The estimated net worth of Oliver Rolf Baumann is at least $8.14 million as of August 27th, 2026. Mr. Baumann owns 5,773,618 shares of Veraxa Biotech stock worth more than $8,140,801 as of September 25th. This net worth evaluation does not reflect any other investments that Mr. Baumann may own. Learn More about Oliver Rolf Baumann's net worth.
How do I contact Oliver Rolf Baumann?: The corporate mailing address for Mr. Baumann and other Veraxa Biotech executives is TALACKER 35, ZURICH, 8001. Veraxa Biotech can also be reached via phone at 41443858450. Learn More on Oliver Rolf Baumann's contact information.
Has Oliver Rolf Baumann been buying or selling shares of Veraxa Biotech?: Over the course of the past ninety days, Oliver Rolf Baumann has bought $75,000.00 of Veraxa Biotech stock. Most recently, on Thursday, August 27th, Oliver Rolf Baumann bought 50,000 shares of Veraxa Biotech stock. The stock was acquired at an average cost of $1.50 per share, with a total value of $75,000.00. Following the completion of the transaction, the director now directly owns 5,773,618 shares of the company's stock, valued at $8,660,427. Learn More on Oliver Rolf Baumann's trading history.
Are insiders buying or selling shares of Veraxa Biotech?: During the last year, Veraxa Biotech insiders bought shares 2 times. They purchased a total of 55,000 shares worth more than $82,650.00. The most recent insider tranaction occured on August, 27th when Director Oliver Rolf Baumann bought 50,000 shares worth more than $75,000.00. Learn More about insider trades at Veraxa Biotech.
Information on this page was last updated on 8/27/2026.

Oliver Rolf Baumann Insider Trading History at Veraxa Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2026	Buy	50,000	$1.50	$75,000.00	5,773,618

Oliver Rolf Baumann Buying and Selling Activity at Veraxa Biotech

Veraxa Biotech Company Overview

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Today's Range

Now: $1.43

$1.43

$1.45

50 Day Range

MA: N/A

2 Week Range

Now: $1.43

$1.27

$27.36

Volume

5,240 shs

Average Volume

501,805 shs

Market Capitalization

$45.10 million

P/E Ratio

N/A

Dividend Yield